Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The choice of neoadjuvant chemotherapy regimen for locally advanced gastric cancer is
controversial. The aim of this study was to compare the short- and long-term outcomes of
XELOX regimen with Docetaxel, S1 and oxaliplatin regimen as neoadjuvant chemotherapy regimen
for locally advanced gastric cancer. The objective of this study is to determine what kind of
neoadjuvant chemotherapy strategy can make subsequent radical surgery feasible and improve
overall survival in patients with locally advanced gastric cancer.